Frequency and predictors of hyperkalemia in patients ≥60 years of age with heart failure undergoing intense medical therapy.

[1]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[2]  J. McMurray,et al.  Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.

[3]  T. Fahey,et al.  Spironolactone use and renal toxicity: population based longitudinal analysis , 2010, BMJ : British Medical Journal.

[4]  M. Pfisterer,et al.  BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. , 2009, JAMA.

[5]  A. Azevedo,et al.  Safety of Spironolactone Use in Ambulatory Heart Failure Patients , 2008, Clinical cardiology.

[6]  L. Ruilope,et al.  Serum Potassium and Clinical Outcomes in the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) , 2008, Circulation.

[7]  Akshay S. Desai,et al.  Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. , 2007, Journal of the American College of Cardiology.

[8]  A. Ducharme,et al.  Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials. , 2006, American heart journal.

[9]  Tom Greene,et al.  Assessing kidney function--measured and estimated glomerular filtration rate. , 2006, The New England journal of medicine.

[10]  M. Pfisterer,et al.  Management of elderly patients with congestive heart failure--design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). , 2006, American heart journal.

[11]  S. Gottlieb,et al.  The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. , 2005, Journal of the American College of Cardiology.

[12]  C. Gross,et al.  Adoption of Spironolactone Therapy for Older Patients With Heart Failure and Left Ventricular Systolic Dysfunction in the United States, 1998–2001 , 2005, Circulation.

[13]  J. Steward,et al.  Tolerability of spironolactone as adjunctive treatment for heart failure in patients over 75 years of age. , 2005, Age and ageing.

[14]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[15]  K. Tamirisa,et al.  Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. , 2004, American heart journal.

[16]  A. Struthers,et al.  Tolerability of spironolactone in patients with chronic heart failure -- a cautionary message. , 2004, British journal of clinical pharmacology.

[17]  B. Palmer.  Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. , 2004, The New England journal of medicine.

[18]  A. Laupacis,et al.  Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study , 2004 .

[19]  D. Atar,et al.  How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? , 2004, Journal of cardiac failure.

[20]  B. Pitt,et al.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. , 2003, The New England journal of medicine.

[21]  E. Mulkerrin,et al.  Spironolactone therapy in older patients--the impact of renal dysfunction. , 2002, Archives of gerontology and geriatrics.

[22]  K. Swedberg,et al.  Comprehensive guidelines for the diagnosis and treatment of chronic heart failure Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology , 2002, European journal of heart failure.

[23]  K. Swedberg,et al.  Guidelines for the diagnosis and treatment of chronic heart failure. , 2001, European heart journal.

[24]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[25]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[26]  B. Pitt,et al.  EPLERENONE POST-ACUTE MYOCARDIAL INFARCTION HEART FAILURE EFFICACY AND SURVIVAL STUDY INVESTIGATORS. EPLERENONE, A SELECTIVE ALDOSTERONE BLOCKER, IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL INFARCTION , 2003 .